KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

A major cross institutional research collaboration aimed at reducing the number of patients harmed in Australia has received $8.4 million in funding in the latest round of National Health and Medical Research Council (NHMRC) program grants. With current research showing that patient harm occurs in 10 per centof hospital admissions, and that less than

Full Post: $8.4 million research grant to improve patient safety in Australia

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.

KAI-1678 also was shown to reverse pain more effectively than gabapentin, an industry-standard comparison in pain research. The preclinical results were presented in two posters at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience , taking place in Washington, DC from November 15 - 19. KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC), is expected to enter Phase 2a clinical testing by the end of 2008.

Stephen D. Harrison, Ph.D., Senior Vice President, Research commented, “The findings being presented at this year’s Society for Neuroscience meeting provide additional validation for our program advancing the first isozyme-selective, epsilon PKC inhibitor in the clinic. The localization of epsilon PKC in pain receptor neurons made this a particularly interesting therapeutic target for the modulation of acute pain. Applying our expertise in PKC and in the delivery of peptides into the cell, we were able to create a promising clinical candidate against this target, which will soon progress into mid-stage trials in patients.”

An estimated 50 million people in the United States suffer from some form of persistent pain, while another 25 million suffer acute pain each year as a result of injury or surgery. According to a survey by the American Pain Society, four out of ten people suffering moderate to severe pain were unable to find adequate pain relief.

About KAI-1678

KAI-1678 is an isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway. Epsilon PKC is a well-validated target for both inflammatory and neuropathic pain in the preclinical, peer-reviewed literature. KAI’s approach is the first to enable the specificity of action required to make epsilon PKC inhibition a viable clinical approach.

KAI-1678 has been shown to be highly effective at reducing pain responses in preclinical models of both neuropathic and inflammatory pain.



Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of

Full Post: Eli Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain

Cylene Pharmaceuticals announced today that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman’s disease, or multiple myeloma. The primary endpoints of the oral dose escalating trial are determination of safety, tolerance and PK properties of CX-4945 and to select the

Full Post: Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2

Dyax Corp. has announced  that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) and has designated the application for Priority Review. Based on this designation, the FDA Prescription Drug User Fee Act (PDUFA)

Full Post: FDA accepts filing and grants priority review for DX-88 for hereditary angioedema

New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous

Full Post: Cymbalta (duloxetine HCl) shown to delay new episodes of depression

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of

Full Post: Febuxostat recommended by panel for treatment of hyperuricemia in patients with gout